A new anti-inflammatory drug, 17-oxo-DHA, when combined with hormones can inhibit the activation of the NLRP3 inflammasome and the release of mature IL-1β.444 Despite attempts to treat COPD patients with therapies targeting inflammasome-related effectors at moderate to severe stages, some randomized clinical trials have not shown significant benefits. The gene discussed is NLRP3; the disease is chronic obstructive pulmonary disease.